| Unique ID issued by UMIN | UMIN000053235 |
|---|---|
| Receipt number | R000060748 |
| Scientific Title | Evaluation of the effect of test food intake on the gut environment |
| Date of disclosure of the study information | 2024/12/26 |
| Last modified on | 2024/07/29 19:41:44 |
Evaluation of the effect of test food intake on the gut environment
Evaluation of the effect of test food intake on the gut environment
Evaluation of the effect of test food intake on the gut environment
Evaluation of the effect of test food intake on the gut environment
| Japan |
Healthy male/female adults
| Not applicable |
Others
NO
To evaluate the effects of test food on gut environment
Safety,Efficacy
VAS (fatigue)
- Intestinal barrier
- Gut microbiota
- Gut metabolites
- Defecation status
- POMS2
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
| Food |
Consumption of the test food 1 (1 pack a day, 4 weeks) -> Consumption of the test food 2 (1 pack a day, 4 weeks)
| 20 | years-old | <= |
| 65 | years-old | > |
Male and Female
(1) At informed consent, male/female subjects aged more than or equal to 20, and less than 65 years old.
(2) Subjects who can show their understanding of the study procedure and agreement with participating in the study by written informed consent prior to the study.
(1) Subjects who regularly use foods that explicitly contain tamarind seed gum as a food additive and have been unable to discontinue them since the time of obtaining consent.
(2) Subjects who are taking food for specified health use, foods with functional claims, or health foods (including supplements) that may affect the study at least three times a week and are unable to maintain the amount and frequency of intake during the study period.
(3) Subjects who are taking medicines (antibiotics, bowel regulators, antidiarrheals, laxatives) at least once a week that could potentially affect the study and whose medication cannot be restricted during the study period (no medication, but eye and nose drops are allowed)
(4) Subjects who are now under other clinical tests with some kind of medicine/food, or participated in those within a month before this trial, or will join those after giving informed consent to participate in this trial.
(5) Subjects who have previous/current medical history of illnesses related to immunity, such as autoimmune diseases, or gastrointestinal diseases.
(6) Pregnant, possibly pregnant, or lactating women.
(7) Subjects who are allergic to medicines and test foods (tamarind seed gum).
(8) Others who have been determined ineligible by the principal/sub investigator.
12
| 1st name | Shinnosuke |
| Middle name | |
| Last name | Murakami |
Metagen, Inc.
Headquarters
997-0052
246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan
+81-235-64-0330
research@metagen.co.jp
| 1st name | Yumewo |
| Middle name | |
| Last name | Suzuki |
MP Gokyo Food & Chemical Co., Ltd.
Planning & Coordination / Research, Development & Technology
530-0001
2-5-25 Umeda, Kita-ku, Osaka
06-7177-6866
yumeo.suzuki@mpgfc.co.jp
Metagen, Inc.
MP Gokyo Food & Chemical Co., Ltd.
Profit organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
2F Daiwa Building, 3-3-10 Nihonbashi-Hongokucho, Chuo-ku, Tokyo 103-0021, Japan
+81-3-6225-9005
IRB@cpcc.co.jp
NO
| 2024 | Year | 12 | Month | 26 | Day |
Unpublished
Completed
| 2023 | Year | 12 | Month | 18 | Day |
| 2023 | Year | 12 | Month | 15 | Day |
| 2023 | Year | 12 | Month | 26 | Day |
| 2024 | Year | 04 | Month | 29 | Day |
| 2023 | Year | 12 | Month | 26 | Day |
| 2024 | Year | 07 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060748